Art

J-GLOBAL ID：201002286060372326   Reference number：10A0429677

膵・胆道癌における分子標的治療の動向 膵癌における分子標的治療の臨床試験と最近の動向

Author (2)： HAGIHARA ATSUSHI (国立がんセ 中央病院 肝胆膵内科) ,  UENO HIDEKI (国立がんセ 中央病院 肝胆膵内科)
Material： 胆と膵  (胆とすい)
Volume： 31  Issue： 4  Page： 355-360  Publication year： Apr. 15, 2010 
JST Material Number： Z0153B  ISSN： 0388-9408  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *pancreatic tumor ,...
Semi thesaurus term： cetuximab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0429677&from=J-GLOBAL&jstjournalNo=Z0153B") }}

JST classification (2)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (9)： Axitinib ,  Erlotinib ,  Gefitinib ,  Gemcitabine ,  Sorafenib ,  BAY-12-9566 ,  Tipifarnib ,  CGP-79787 ,  Marimastat

Reference (19)：

• Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
• Nakachi K, Okusaka T, Funakoshi A, et al.: A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ECCO 15, 34th ESMO Abst 6590, 2009.
• O’Reilly EM: Pancreatic adenocarcinoma: new strategies for success. Gastrointest Cancer Res 3: S11-15, 2009.
• Sail MW: Pancreatic cancer: is this bleak landscape finally changing? Highlights from the ’43rd ASCO Annual Meeting’. Chicago, IL, USA. June 1-5, 2007. Jop 8: 365-373, 2007.
• Vervenne W, Bennouna J, Humblet Y, et al.: A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 26: Abst 4507, 2008.

Terms in the title (6)： 膵 ,  胆道癌 ,  分子標的治療 ,  動向 ,  膵癌 ,  臨床試験